Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.53 ▲ +0.00
(0.00%)
MKT CAP: $102.5M • VOL: 1.20M
52W L $1 52W H $12
ROARABLE / RQD
E • 34/100
PIOTROSKI
2 / 9
ENGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-10-31 | FY 2024
FILED 2024-10-31 | FY 2023
FILED 2023-10-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$123.2M | -$62.3M | -$26.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$117.3M | -$55.1M | -$99.9M |
| EBITDA (Normalized) | -$122.0M | -$61.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$99.2M | -$48.3M | -$24.7M |
| Capital Expenditures (CapEx) | $1.5M | $925.0K | — |
| Free Cash Flow (FCF) | -$100.7M | -$49.2M | -$24.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -39.7% | -26.2% | — |
| Cash & Short-Term Equivalents | $36.6M | $62.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $281.5M | $249.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ENGN.